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Introduction
The expressions elderly and geriatric are used widely in modern 
medicine and are defined as terms describing the old or aged 
person1. However, when asked to specifically define old age, there 
is no universally accepted interpretation in place2. The World 
Health Organisation (WHO) proposes that most countries 
define elderly as being over the age of 65 years, generally 
recognised as retirement age3. In our society, this demographic 
is unfortunately susceptible to misconceptions and ageist 
stereotypes, creating complexities in the medical management of 
the eldly.
We are currently faced with an aging population, which is 
rapidly growing worldwide. Healthy life expectancy is increasing 
and people are living for longer periods of time4. In 2010 the 
number of over 65’s was estimated to be around 534 million, 
the equivalent of 8% of the worlds’ population5. By 2021, this 
is predicted to rise to approximately 10%6. Moreover, by 2050, 
this is anticipated to almost triple in number to 1.5 billion; 
16% of the world’s population will be of retirement age2. As a 
result of these demographic changes, it could be argued that 
our accepted definition of elderly and the associated age of 
65 years is no longer medically relevant and it should be changed 
to an age of at least 75 years and over; perhaps this cut off would 
provide greater meaning. Nonetheless in the current era of 
geriatric medicine, age alone is no longer enough to characterise 
an individual6. 
Age is an indirect risk factor for cancer; extended life 
duration is coupled with increased exposure to carcinogenic 
factors alongside greater time for the accumulation of genetic 
changes, which could eventually result in the generation of 
a tumor. Two thirds of cancer occurs in the over 65-year age 
group, a noteworthy proportion of individuals6. Statistics 
collected between 2009 and 2011 by Cancer Research UK 
present the male to female ratio of diagnosis as 1.06:1 per year 
(60,828:57,221) within the elderly aged over 75 years7,8. About 
70% of cancer related deaths occur within this population9. 
The prevalence of certain cancers varies with gender. In order 
of decreasing incidence, prostate, lung, and bowel cancers 
contribute to 57% of cancers diagnosed in elderly males. Females 
are most commonly affected by breast cancer (21%), followed by 
lung, bowel, stomach, and uterine cancer10. 
Societal conceptions from the past have created ageist 
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stereotypes; old age is associated with frailty and the elderly 
are perceived to be destined for deterioration and loss of 
independence11. Cancer within the elderly is also subject to these 
stereotypes, with elderly cancer patients considered by some not 
as likely to recover as younger patients with cancer. However, 
this is not necessarily the case and currently elderly members 
of the community are often able to work and play an active role 
in society12. Ageism is defined as ‘an attitude that discriminates, 
separates, stigmatises or otherwise disadvantages older adults 
on the basis of chronological age’13. In healthcare, it alludes to 
the idea that considerable deterioration is always a normal part 
of aging and that older individuals may not benefit as much as a 
younger individual from certain treatment, and therefore should 
perhaps not be offered it. Under-treatment in the geriatric 
patient is reinforced by the ageist approach to care and although 
this approach is built on the basis of avoiding harm, it does not 
follow the principles of consent, capacity and acting in a patient’s 
best interest14. We summarise and review the current concerns 
regarding elderly management and treatments utilised for the 
management of oncological disease in the elderly, and discuss 
the impact of under-treatment within this population.
Issues associated with the management of 
the elderly
The management of geriatric patients does not come without 
challenges. The aging process is accompanied by multisystem 
physiological changes in the body, including deterioration of 
vision and hearing, reduced kidney function, reduced gastro-
intestinal motility, reduced efficiency of the cardiovascular 
and respiratory systems, decreased bone density, and reduced 
mobility to mention a few15. Although these changes are natural 
they render the elderly less able to manage, with a reduced 
reserve for stresses placed on the body and more susceptible to 
pharmacokinetic and pharmacodynamics interactions, which 
may lead to toxicity2.
Any psychological or cognitive decline can alter the amount of 
patient support required, which may be accompanied by difficult 
social or financial circumstances16. Limited social support and 
difficulty accessing transport and healthcare create further 
hurdles in the pathway to obtaining treatment for geriatric 
patients. All of these factors may contribute to the effectiveness 
of treatment and a patients’ prognosis. Evidence suggests that 
good family support networks increase patient tolerance towards 
more extensive treatment regimens1. It is clear that even elderly 
patients of good health still have different health needs compared 
to younger patients8.
Financial burden of cancer care in the 
elderly
The cost of treatments can vary globally, depending on the 
intervention, the site, and the stage (severity) of cancer being 
treated. If treatment costs continue to rise annually by 2%; 
breast and prostate cancers will produce the largest increases in 
expense, 32% and 42% relatively, simply due to the fact that these 
cancers will remain most prevalent in the population2. 
According to Macmillan Cancer Support, the financial impact 
of cancer on an individual is most considerably influenced by age, 
the stage of their cancer, and their social class (employment and 
income)17. In addition to treatment costs, these patients must be 
prepared to fund transportation to and from appointments and 
perhaps to specialist centres. Cancer may also result in increased 
costs for the family of the patient; addition funding is required 
to support the elderly patient, due to declining ability for the 
patient to manage their required activities of daily living. 
A report published by the department of health in 2014 
presented figures regarding emergency hospital admissions. 
The years 2012/2013 saw 82,600 admissions due to cancer, 
representing 3.7% of all emergency admissions. Geriatric patients 
may sometimes be referred to as ‘hazards of hospitalisation’, 
simply due to their greater risk of hospital related complications. 
These include malnutrition, pressure ulcers, falls, delirium 
and hospital acquired infection18. Emergency admissions to 
hospital can be expensive and elderly patients may have a higher 
occurrence of re-admission. Prevention of this is therefore a 
collective objective in the health service. 
With a  grow ing bank of  people  w ithin  the  elder ly 
demographic and an inevitable rise in the prevalence of cancer, 
we need to work towards providing optimal treatment in a cost 
effective manner. With limited resources and funding, there is 
a need to provide this optimal care to everyone, including the 
geriatric population. 
Management of geriatric oncology patients
There is plenty of evidence to suggest that under-treatment of the 
elderly is a very real issue. This under-treatment arises for many 
reasons. Firstly, the lack of elderly patients in clinical trials has led 
to insufficient evidence and gaps in our knowledge as to what are 
the most effective treatments for geriatric oncology patients. This 
in turn results in a lack of guidelines to support evidence-based 
decisions, and so patients may not receive the most effective 
treatment and are undertreated. In addition, iatrogenic factors 
play a role. The ageist approach to care of geriatric patients gives 
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rise to bias and misconceptions as to what is best for the patient 
and which treatments they can tolerate. Lower risk and less 
aggressive interventions may appear a more attractive option 
to physicians, in order to avoid patient morbidity or mortality. 
Nonetheless, 15,000 older cancer patients die prematurely due 
to this approach and under-treatment leads to a reduced 5-year 
patient survival1,2.
A retrospective evaluation reported data involving 212 
patients over 80 years old with newly diagnosed breast cancer at 
the University of Texas MD Anderson Cancer Centre between 
1989 and 2004. Those treated only with primary endocrine 
therapy in comparison to endocrine therapy in combination with 
surgery had a significant reduced survival (P=0.001). The study 
also illustrated that 57% of these patients with a huge proportion, 
were under-treated when consulting the existing guidelines19. 
The conclusions from this study held great importance. It not 
only highlighted the benefits of multidisciplinary therapy in 
the elderly, but also emphasised that under-treatment leads to 
reduced cancer survival and impaired prognosis1.
Diffuse large B-cell lymphoma is a subtype of non-Hodgkin’s 
lymphoma and a malignancy that is increasing in prevalence 
throughout the elderly population. It is manageable and 
potentially curable, like several other cancers. In concordance 
with the reasons already mentioned, geriatric patients are largely 
under-represented in clinical trials and so treatment decisions for 
this cancer is generally based on evidence from younger patients. 
As a result some patients are given sub-optimal therapy in an 
attempt to avoid toxicity, perhaps having negative implications 
on prognosis. Alternative regimens may be considered for 
geriatric patients which would be deemed as under-treatment 
in younger populations. The issue of geriatric under-treatment 
is therefore very apparent. The international society of geriatric 
oncology (SIOG) recently chose to review the treatment of these 
patients and outline more effective guidelines for management 
to target this potentially detrimental care20.
There are an increasing number of treatments and potential 
options now available for the medical and surgical oncological 
management of the geriatric patient. Current treatment pathways 
available include surgery, radiotherapy, chemotherapy, biological 
therapies, pharmacological treatment and endocrine therapy. 
There are a handful of further treatments also available that are 
not regarded as frontline. All of these treatments may be used 
individually as monotherapy, or in collaboration with adjuvant 
supportive treatment.
Surgical
According to the Royal College of Surgeons England, there 
were 4.7 million surgical admissions in 2013-201421. The most 
common procedures performed were hernia repairs (120,198) 
followed by hip replacements (115,758) and knee replacements 
(81,590). Despite the prevalence of cancer w ithin the 
population, cancer related surgery did not appear amongst the 
top 10 surgeries performed. 
Surgery is perhaps the branch of treatment that causes most 
debate. It is perhaps misconceived by some health professionals 
and certainly by the public that old age is contra-indication to 
oncological surgery. Surgery is invasive and inevitably there are 
greater risks associated, including lengthy hospital stays, ICU 
admissions and undesirable complications such as premature 
mortality. Despite this, surgery in an older patient can provide 
similar success with cancer treatment as in younger patients 
with well-regarded evidence to support the feasibility of surgery 
within this age group1,22. It is important to remember that 
surgical therapy can be curative; surgery is reported as ‘the most 
effective cancer-ablative therapy’22. Surgical resection of cancer 
can reduce costs by removing the need for ongoing long-term 
treatments to manage the cancer in elderly patients. 
Surgical interventions come in several forms, ranging from 
simple local excision to the removal of entire glands such as 
in a mastectomy23. As patients remain healthier for longer, the 
breadth of patients within the surgical group is increasing. Lung 
cancer is characterised by an association with age22. Over 65% of 
patients with lung cancer are over the age of 65 years when they 
are initially diagnosed. Furthermore, 25% of patients diagnosed 
are 75 years or older with 30% of patients who die from lung 
cancer within this latter demographic. A lung lobectomy is the 
current standard procedure for patients of any age, and carries an 
operative mortality risk of 1.4%22. Results from randomised trials 
suggest that there is no increased mortality risk related to this 
surgery with proceeding age24. Further research is required to 
identify peri-operative mortality rates that are representative for 
the elderly population but these figures suggest that the elderly 
patient should not be excluded from surgical interventions on 
the basis of age alone.
Between the years 1989 and 1999, Bouchardy et al.25 
performed a study reviewing 407 breast cancer patients over 80. 
The study demonstrated that under-treatment of the elderly was 
a very real issue and that treatment provided was independently 
associated with age. Of all the participants, 12% of women had 
no treatment, 33% had a mastectomy, 32% received hormone 
therapy in the form of tamoxifen, 14% had breast conserving 
surgery with adjuvant therapy and 7% had breast conserving 
surgery alone25. The primary outcome (5-year specific breast 
cancer survival) produced notable findings. Five-year survival 
figures were presented as 46% for women with no treatment and 
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51% for those given tamoxifen. Contrasted with an 82% 5-year 
survival from the mastectomy patients and a 90% survival from 
those who had breast conserving surgery and adjuvant treatment, 
not only do these results suggest that under-treatment leads to 
reduced survival and worse prognosis, they highlight the benefits 
of surgical intervention for geriatric patients. 
Nevertheless although surger y should be considered 
optimistically, it remains a high-risk intervention. The overall 
peri-operative mortality rate stands at 1.2% for the general 
population within 30 days of surgery and this rate substantially 
rises with increasing age26-29. The risk of death rises significantly 
to 19.8% with major surgery in the over 90s age group30. It is 
important to remember that proposing surgery to prolong life 
still carries a considerable risk (Table 1). 
The mortality associated with surgical intervention is not 
only associated with age but with the nature of the surgery 
itself. The risk associated with aggressive, invasive surgery such 
as pancreatic or oesogastric surgery is not comparable to the 
risks associated with breast or lung cancer surgery. However, a 
study driven by the current changing demographics and elderly 
population reviewed 438 patients over a 9-year period following 
a pancreatic resection. The study concluded that elderly patients 
can safely endure invasive pancreatic surgery and that age alone 
should not exclude them from this group. Nevertheless there was 
still significant risk of morbidity, poor prognosis and reduced 
quality of life as a result31. 
A further concern is the issue of screening for cancer in the 
elderly population. Perhaps the importance of early diagnosis 
and prevention is overlooked and not stressed sufficiently within 
the geriatric population. Earlier diagnosis could reduce the need 
to high risk emergency surgery in this population.
In an era where cancer is becoming increasingly by prevalent 
and diverse, there is no longer room for a ‘one criterion fits all’ 
parameter in the form of an age threshold. The surgical approach 
should arguably never be excluded despite patients’ age. Patients 
can be individually assessed and evaluated for their fitness for 
surgery using various tools. Using a more holistic approach 
and considering a combination of factors (including health 
assessment), many elderly individuals may be deemed fit for 
surgical treatment of their cancer. Fear associated with surgical 
outcomes in addition to a lack of guidelines leads to surgical 
options being inadequately considered, resulting in under-
treatment of these geriatric cancer patients.
Medical
The UK budget for the cancer drug fund was raised from 200 million 
pounds in 2013/2014 to an estimated 340 million pounds in 
April 201532. However, earlier in 2015 several cancer drugs were 
removed from The National Health Service (NHS) funding 
simply due to their expense. Examples include lapatinib, eribulin, 
and everolimus, all used in the treatment of breast cancer; 
pemetrexed, which is used to treat lung cancer, and cabazitaxel, 
used for late-stage hormone resistant prostate cancer. These cut 
backs are estimated to affect almost 8,000 patients in the UK, 
many of them with advanced disease and perhaps likely to be 
geriatric33.
With advancements in the medical management of cancer, 
recent years have seen a decline in the incidence of mortality 
due to breast cancer in younger women, however, this trend 
is not been observed in older women1. Advancements in 
pharmaceutical treatments created by the drug industry drive 
the development of more effective medicinal therapies for use 
in oncology. However, this progression in efficacy is inescapably 
coupled with increasing expense and financial repercussion. 
An example is traztuzumab (Herceptin) which is used in the 
treatment of breast cancer. A course of traztuzumab costs on 
average approximately 25,000 pounds with the cost effectiveness 
estimated at 400,000 pounds per recurrence prevented6. We 
will become ever more reliant on these drugs in the future but 
unsurprisingly many patients may not be able to afford to fund 
these treatments privately.
Evidence suggests that endocrine therapy should not be used 
in geriatric patients at all, particularly with those that are frail 
or those with tumors that are at low risk34. This is because these 
hormonal therapies may cause several unfavourable side effects 
such as deep vein thrombosis; bone loss and musculoskeletal 
conditions. These negative effects largely outweigh the potential 
therapeutic benefit in elderly patients. However, as with all 
treatments there are exceptions to the rule and the decision 
must be made on an individual basis. Medical management of 
oncology in the elderly should not be dismissed purely on an 
impression of ability to tolerate side effects, as this can lead to 
under-treatment within this population. For example, with the 
Table 1 Mortality rates during surgery split by age groups (34-38)
Age (years) Risk of peri-operative mortality (%)
<59 1.2
60-69 2.2
70-79 2.9
80-89 5.8-6.2
≥90 8.4
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treatment of breast cancer, hormonal therapy can be used in 
both young and older patients; it remains the adjuvant therapy 
most readily used in older women due to the predominance of 
cases with estrogen receptor (ER) expression. Tamoxifen would 
perhaps be recommended for use in geriatric care. Tamoxifen 
also helps to prevent reduced bone density, a physiological 
change associated with old age. The use of any drug in the 
geriatric patient requires close monitoring35.
Chemotherapy
The cost of chemotherapy or radiotherapy per episode, which 
may be comprised of 3-4 sessions, can be as overwhelming as 
35,000 pounds36. Unsurprisingly, the use of chemotherapy in 
geriatric oncology has the smallest evidence base. The potential 
toxicity of treatment also can make clinical trials unethical 
for the geriatric population. The narrow therapeutic index of 
chemotherapeutic drugs makes dose selection particularly 
complex. An additional physiological change associated 
with aging is reduced function of the CYP2 enzyme9. This 
biological catalyst plays a key role in the metabolic pathway 
involved in the action of chemotherapeutic drugs, important 
to minimising toxicity. The current lack of evidence creates a 
barrier in establishing the effectiveness of this treatment in older 
patients. Current practice suggests that adjuvant chemotherapy 
is indicated only after careful consideration of a combination of 
factors, such as recurrence risk and concurrent mortality risk26. 
In one study, 318 patients ranging from age 80 to 92 years were 
reviewed between 2005 and 2010. All participants were receiving 
chemotherapy for solid malignant tumors and the consequences 
of this treatment were investigated. The primary outcome of 
the study was discontinuation of chemotherapy due to toxicity 
and there were several secondary outcomes regarding adverse 
effects. Chemotherapy was first line for 89% of participants; 
41% ordered an upfront dose reduction, 32% withdrew from 
treatment due to the toxicity and notably 32% of patients were 
hospitalised27. Inspite of a small study, this evidence quite clearly 
implies that chemotherapy in older patients poses quite serious 
risks and the requirement for effective methods of patient 
selection are emphasised. Clinicians must question whether 
the risks presented are worthwhile for the therapeutic benefit 
achieved from chemotherapy treatment of oncology in geriatric 
patients. 
Several randomised trials have been published regarding 
metastatic colorectal cancer to investigate reduced-dose 
chemotherapy options and assess predictors of outcome in frail 
patients with advanced colorectal cancer. A study published 
in 2011 once more highlighted that although often treated 
with chemotherapy, the elderly are under-represented in such 
clinical trials. FOCUC2 aimed to investigate reduced-dose 
chemotherapy options and assess outcomes in frail patients with 
advanced colorectal cancer37. Similarly further trials include 
FFCD 2001-02, AVEX and PRODIGE 20. Trials are ongoing 
and therefore display that progress is being made to improve the 
evidence base for oncological treatment of geriatric patients.
In addition to this, a promising instrument developed to 
predict chemotherapy toxicity by the Cancer and Ageing 
research group has been recently trialled and supported in 
several clinical environments including geriatric oncology. Also, 
the first prospective clinical trial regarding elderly women and 
ovarian cancer is being supported by the Elderly Taskforce of 
the Gynaecological Oncology group. The American Society 
of Clinical Oncology (ASCO) plays an active role in geriatric 
oncology, introducing a geriatric oncology issue exploration 
team, establishing further educational materials, creating the 
B.J Kennedy Award for Excellence in Geriatric Oncology 
and establishing a geriatric oncology element to the Cancer 
Education Committee. All these interventions aim to provide 
evidence based guidance for the management of oncology in the 
geriatric population, aiming to improve the future of geriatric 
oncology29.
Radiotherapy
Evidence suggests than any benefits of radiotherapy appear 
to decrease as age increases1. R adiotherapy can be ver y 
debilitating, particularly to older patients, due to the effect on 
the entire body, as well as complications locally where applied. 
Radiotherapy treatment can be an ongoing commitment, 
requiring multiple sessions over a long period of time. 
This can be physically taxing, and is accompanied by the 
financial burden of retreatments. This may lead to a lack of 
compliance or withdrawal from therapy, as patients cannot 
tolerate the treatment. A recent publication in the European 
Geriatric Medicine journal re-evaluated some retrospective 
data regarding the treatment of breast cancer patients over 
65 years of age. The authors investigated 79 patients who had 
been treated and followed-up in the Cumburiyet University 
Medical Oncology Department and found that 66.6% of patients 
receiving chemotherapy and/or radiotherapy had related side 
effects38. However, the study concluded that neither therapy was 
more toxic in elderly patients compared to younger patients, 
therefore treatment of each age group should be equivalent38.
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Appropriate health assessment and 
treatment for geriatric oncology patients
The treatment of geriatric patients may be complicated by 
a spectrum of physical, psychological and social challenges. 
The factor of age alone cannot be just justified as the reason 
for treatment selection or dismissal. As with any age group, 
each patient is different and must be individually evaluated to 
establish the most effective management. Within the general 
population, standard methods of medical evaluation are effective 
but are not sufficient for assessment of elderly patients, as they 
do not account for factors such as cognitive decline, reduced 
mobility or iatrogenic disorders1. 
Acknowledgement of the importance of the initial evaluation 
in the medical community has led to the creation of several tools 
for bespoke assessment, which play a key clinical role. A useful 
example is the comprehensive geriatric assessment (CGA). 
The use of this evaluation enables treatment selection acting 
in the patient’s best interest as it removes any ageist bias. This 
standardised tool reviews several domains (Table 2)39. 
A recent study evaluating the use of the CGA on patients 
after hospital admission came to several statistically significant 
conclusions40. The meta-analysis found several benefits of 
performing a CGA including a reduction in patient deterioration 
and a decreased incidence of death (P=0.001). Evidence was 
also presented showing that elderly patients were more likely to 
survive hospital admission, return home, and remain alive for 
the return home and remain alive for the following year if a CGA 
was performed during their inpatient stay. This research clearly 
highlights the effectiveness of geriatric assessment. In addition to 
these advantages an overall benefit in cognitive measures was also 
shown (P=0.02)40. These conclusions were reinforced by another 
study, which also presented benefits of an inpatient CGA vs. no 
CGA in 10,427 participants from a varied elderly population41. 
Twenty randomised control trials were included together in a 
systematic review. In addition to the benefits expressed in the 
previous study, this review concluded that ‘for every 100 patients 
receiving a CGA, three more will be alive in their own homes’41. 
It is interesting how the use of such a simple methodological tool 
can make such a difference to quality of life. Additional recently 
adopted and regularly used tools include the mini-geriatric 
and G8 score. There is a wealth of evidence to suggest that 
these methods of evaluation are particularly effective. A study 
evaluating the G8 and f TRST screening tools in geriatric care 
concluded that both measures were effective for assessing patients 
and determining their prognosis with regards to functional 
decline and overall survival. A total of 937 patients aged over 
70 years were included. These individuals had a malignant tumor 
and a new cancer event requiring a treatment decision42.
Similar positive results were shown by a small study carried 
out involving elderly patients with different digestive cancers. The 
study aimed to assess the feasibility of mini geriatric assessment 
(MGA) in the adaptation of anticancer treatments and help 
make treatment decisions in these geriatric patients. The study 
concluded that the assessment could help gastroenterologists 
adapt treatment plans for oncological treatment43. There are 
also further methods of frailty assessment such as the Charlson 
Comorbidity Index and the ‘Multidimensional assessment 
for cancer in the elderly ’ also known as MACE. Through 
consideration of several factors, these tools can assist in 
determining prognosis. 
Frailty assessment has been readily adopted into professional 
practice in geriatric medicine. Macmillan Cancer Support, 
backed by Age UK has collaborated with the department of 
health to fund further studies on older cancer patients, an 
important step towards valuable research and making progress6. 
On the basis of the clear advantages of geriatric assessment, 
funds will also be dedicated towards establishing new means of 
evaluation to improve selection of cancer treatment. In addition, 
Macmillan aims to address current issues of ageist prejudice. 
Table 2 Domains reviewed in CGA
Medical Functional Mental health Social Environmental
Co-morbidities Gait & balance Cognition Informal support Use of telehealth technology
Disease severity Exercise status Mood Social network Transport
Medication review Activities of daily life 
(ADLs) 
Anxiety Family, friends & visitors Home comfort & safety
Nutritional status Instrumental ADLs Fears Daytime activities Occupational health
Other problems Eligibility for care resources Accessibility to local resources 
and facilities 
CGA, comprehensive geriatric assessment.
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All these methods of geriatric assessment have resulted in 
changes in treatment proposals and have been particularly 
effective in evaluating whether a patient is fit for surgery22,41. 
Patient health assessment in the geriatric population allows for a 
comprehensive evaluation of patient health and frailty, helping to 
overcome the issue of under-treatment due to health perception 
based on age alone. 
Appropriate treatment of geriatric cancer patients can lead 
to prognostic improvements. Two cohorts of patients aged 
70 years or older were compared in a study contrasting the 
outcomes and effectiveness of oncogeriatric care vs. standard 
care. The cohorts had similar baseline characteristics such as 
their stage of breast cancer. The results presented how patients 
receiving standard care obtained fewer modalities of treatment, 
particularly less surgery, chemotherapy and hormone therapy 
(P<0.001). More importantly, the three-year mortality rate 
for the group receiving standard care was 71% (95% CI, 61%-
83%) in comparison to 58% (95% CI, 42%-75%) for patients 
in the oncogeriatric care group. This study concluded that 
more bespoke, cancer-specific care is beneficial in reducing 
mortality rates and provides an improved prognosis. The study 
showed how more appropriate care could change survival and 
emphasised the requirement for further research to quantify 
the extent of these improvements44. 
Future care
Fortunately some progress has been made in the right directions. 
A number of recent trials by the National Cancer Institute 
(NCI) have demonstrated the improvement in clinical research 
regarding oncogeriatric medicine. The institute acknowledges the 
necessity and clinical requirement for further focused research 
on geriatric patients45. However, barriers still exist for research 
in geriatric cancer patients. A study published in 2003 by the 
ASCO investigated the barriers to clinical trial participation by 
the older women with breast cancer. The study aimed to establish 
whether the under-representation was due to fewer older women 
being asked to take part or conversely more of them declining 
to participate. Seventy-seven pairs were assigned consisting of 
one older woman aged 65 or above and one younger woman 
under 65 and these pairs were interviewed about their reasons 
for participation or refusal. Clinicians offering trials were also 
questioned about their motives for offering or not offering a trial 
to an individual. About 68% of younger patients were offered 
a trial compared to 34% of patients over 65 (P=0.004). The 
most influential reasons for trial offering appeared to be age and 
stage of cancer. Once offered a trial, there was no significant 
difference between participation (P=0.67), 56% of younger 
patients accepted and 50% of older patients did the same46. The 
study concluded that the largest obstacle for older women for 
contributing to a trial was the physicians’ perception about age 
and tolerance for potential toxicity, both influenced by an ageist 
approach. 
Conclusion 
Current opinions and evidence regarding geriatric oncology 
and under-treatment all appear to draw similar conclusions. It is 
universally agreed that there is a lack of evidence for management 
of elderly cancer patients. Involvement of more elderly patients 
in clinical trials will allow evidence-based decisions to be made 
when considering the most effective management for geriatric 
oncology patients. The risks associated with the treatment 
options for cancer are present regardless of age; awareness of age 
is an important factor, but this prejudice needs to be removed. 
The use of tools enabling geriatric and frailty assessment, such 
as the CGA, helps to surpass exclusion of treatment due to any 
age discrimination. Every patient should be educated about all 
available treatment options to allow them to make an informed 
decision. In order to make this informed decision and consent, 
an individual must have capacity. This means they must be 
able to understand, retain and weigh up information and then 
communicate a decision28. Assumptions should never be made 
regarding capacity based on age and it should be presumed 
that every patient has capacity until proven otherwise. Elderly 
patients should be fully informed about treatment and no 
information should be withheld or overlooked on the basis of 
their age. Such presumptions and perceived lack of capacity can 
lead to under-treatment19. 
The future of geriatric oncology involves taking a large stride 
away from the traditional paternalistic approach to treatment, 
moving to a more patient-centered, tailored approach with 
well-integrated standardised holistic assessment2. Guidelines 
implemented by institutions such as the SIOG are beginning 
to recognise the importance of an individualistic methodology 
not influenced by age. They are endorsing steps towards a more 
equivalent approach to care. Without such guidelines we are left 
with a spectrum of care offered which often results in under-
treatment of elderly cancer patients and rarely provides the 
optimal care geriatric patients need. 
Conflict of interest statement
No potential conflicts of interest are disclosed. 
282 Swaminathan et al. Geriatric oncology: problems with under-treatment within this population
References
1. Oxford Dictionary. Definition of Elderly in English from 
the Oxford Dictionary. Available online: http://www.
oxforddictionaries.com/definition/english/elderly [Accessed 
22nd August 2015].
2. Swaminathan V, Audisio RA. Geriatric oncology: a problem and 
solution. Oncology News 2012:7:12-13.
3. WHO World Health Organisation. Definition of an older or elderly 
person. Available online: http://www.who.int/healthinfo/survey/
ageingdefnolder/en/ [Accessed 22nd August 2015].
4. The World Bank. Life expectancy at birth, total (years). Available 
online: http://data.worldbank.org/indicator/SP.DYN.LE00.IN
5. National institute on aging, national institutes of health, u.s. 
department of health and human services. Global health and 
aging. available online: http://www.who.int/ageing/publications/
global_health.pdf
6. Swaminathan V, Audisio RA. Cancer in older patients: an analysis 
of elderly oncology. Ecancermedicalscience 2012;6:243.
7. Cancer research UK: Cancer incidence statistics. Available online: 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/incidence [Accessed on 22nd August 2015].
8. Vicini E, Swaminathan V, Audisio RA. Management of breast 
cancer in elderly patients. Clin Pract 2014:11:59-69.
9. Walko CM, McLeod HL. Personalizing medicine in geriatric 
oncology. J Clin Oncol 2014;32:2581-2586.
10. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. 
Estimates of the cancer incidence and mortality in Europe in 2006. 
Ann Oncol 2007;18:581-592.
11. Masse M, Meire P. Is ageism a relevant concept for health care 
practice in the elderly? Geriatr Psychol Neuropsychiatr Vieil 
2012;10:333-341.
12. Meyer H. The Guardian. Older, healthier and working: britons say 
no to retirement. Available online: http://www.theguardian.com/
society/2013/aug/24/working-britons-retirement [Accessed 23rd 
August 2015].
13. Medical dictionary. Definition of ageism by medical dictionary. 
Available online: http://medical-dictionary.thefreedictionary.
com/ageism [Accessed on 22ndAugust].
14. Good Medical Practice. Consent: Patients and doctors making 
decisions together. general medical council. Available online: 
http://www.gmc-uk.org/guidance/ethical_guidance/consent_
guidance_index.asp [Accessed 22nd August 2015].
15. Raza A, Raza SA, Qamar MF, Llaqat A. Human brain; physiological 
alterations occurring underlying process of aging. Professional 
Med J 2015;22:522-526.
16. Wilkinson R, Marmot M, editors. Social Determinants of Health: 
The Solid Facts. Second Edition. Denmark: World Health 
Organisation; 2003.
17. Macmillan Cancer Support. Cancers Hidden Price Tag: 
Revealing the cost behind the illness. Available online: http://
www.macmillan.org.uk/Documents/GetInvolved/Campaigns/
Costofcancer/Cancers-Hidden-Price-Tag-report-England.pdf
18. Creditor MC. Hazards of hospitalization of the elderly. Ann Intern 
Med 1993;118:219-223.
19. August DA, Rea T, Sondak VK. Age-related differences in breast 
cancer treatment. Ann Surg Oncol 1994;1:45-52.
20. Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa 
P, Aapro M, et al. Approach to therapy of diffuse large B-cell 
lymphoma in the elderly: the International Society of Geriatric 
Oncology (SIOG) expert position commentary. Ann Oncol 
2015;26:1058-1068.
21. Royal College of Surgeons. Surgery and the NHS in Numbers. 
Available online: https://www.rcseng.ac.uk/media/media-
background-briefings-and-statistics/surgery-and-the-nhs-in-
numbers [Accessed 20th August 2015].
22. Korc-Grodzicki B, Downey RJ, Shahrokni A, Kingham TP, Patel 
SG, Audisio RA. Surgical considerations in older adults with 
cancer. J Clin Oncol 2014;32:2647-2653.
23. Swaminathan V, Spiliopoulos MK, Audisio RA. Choices in 
surgery for older women with breast cancer. Breast Care (Basel) 
2012;7:445-451. 
24. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, 
Landreneau RJ, et al. Morbidity and mortality of major pulmonary 
resections in patients with early-stage lung cancer: initial results of 
the randomized, prospective ACOSOG Z0030 trial. Ann Thorac 
Surg 2006;81:1013-1019; discussion 1019-1020.
25. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, 
Schäfer P, et al. Undertreatment strongly decreases prognosis of 
breast cancer in elderly women. J Clin Oncol 2003;21:3580-3587. 
26. Bernardi D, Errante D, Gallligioni E, Crivellari D, Bianco A, 
Salvagno L, et al. Treatment of breast cancer in older women. Acta 
Oncol 2008;47:187-198.
27. The Royal College of Surgeons of England. Access all ages: 
Assessing the impact of age on access to surgical treatment. 
Available online: https://www.rcseng.ac.uk/publications/docs/
access-all-ages
28. General Medical Council. Consent guidance: part 3: capacity 
issues. Available online: http://www.gmc-uk.org/guidance/
ethical_guidance/consent_guidance_part3_capacity_issues.asp 
[Accessed: 22nd August 2015].
29. Lichtman S, Hurria A, Jacobsen P. Geriatric oncology: an overview. 
J Clin Oncol 2014;32:2521-2522.
30. Jenkins K, Baker AB. Consent and anaesthetic risk. Anaesthesia 
2003;58:962-984. 
31. Oliveira-Cunha M, Maldr DJ, Aldouri A, Morris-Stiff G, Menon 
283Cancer Biol Med Vol 12, No 4 December 2015
VK, Malvern Smith A. Results of pancreatic surgery in the elderly: 
is age a barrier? HPB 2013;15:24-30.
32. NHS England 2015: News. NHS increases budget for cancer 
drugs fund from £280 million in 2014/15 to an expected £340 
million in 2015/16. Available online: https://www.england.nhs.
uk/2015/01/12/cancer-drug-budget/
33. Donnelly L, Walton G. 25 cancer drugs to be denied on 
NHS. Available online: http://www.telegraph.co.uk/news/
politics/11340860/25-cancer-drugs-to-be-denied-on-NHS.html 
[Accessed 22nd August 2015].
34. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, 
Senn HJ, et al. Strategies for subtypes--dealing with the diversity 
of breast cancer: highlights of the St. Gallen International Expert 
Consensus on the Primary Therapy of Early Breast Cancer 2011. 
Ann Oncol 2011;22:1736-1747.
35. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, 
et al. Skeletal effects of exemestane on bone-mineral density, bone 
biomarkers, and fracture incidence in postmenopausal women 
with early breast cancer participating in the Intergroup Exemestane 
Study (IES): a randomised controlled study. Lancet Oncol 
2007;8:119-127.
36. NHS: what we give and what we get. Available online: http://
news.bbc.co.uk/2/hi/programmes/breakfast/4898158.stm
37. Seymour MT, Thompson LC, Wasan HS, Middleton G, 
Brewster AE, Shepherd SF, et al. Chemotherapy options in 
elderly and frail patients with metastatic colorectal cancer 
(MRC FOCUS2): an open-label, randomised factorial trial. 
Lancet 2011;377:1749-1759. 
38. Seker MM, Yucel B, Seker A, Ay Eren A, Bahar S, Celasun G, et al. 
Treatment and prognosis of breast cancer in elderly: different from 
young patients? Eur Geriatr Med 2014;5:261-264.
39. British Geriatrics Society. Comprehensive assessment of the frail 
older patient. Available online: http://www.bgs.org.uk/index.
php?option=com_content&view=article&id=195
40. Ellis G, Whitehead MA, Robinson D, O'Neill D, Langhorne P. 
Comprehensive geriatric assessment for older adults admitted 
to hospital: meta-analysis of randomised controlled trials. BMJ 
2011;343:d6553. 
41. Ellis G, Langhorne P. Comprehensive geriatric assessment for 
older hospital patients. Br Med Bull 2005;71:45-59. 
42. Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, 
Milisen K, et al. Performance of two geriatric screening tools in 
older patients with cancer. J Clin Oncol 2014;32:19-26. 
43. Aparicio T, Girard L, Bouarioua N, Patry C, Legrain S, Soulé JC. 
A mini geriatric assessment helps treatment decision in elderly 
patients with digestive cancer. A pilot study. Crit Rev Oncol 
Hematol 2011;77:63-69. 
44. van de Water W, Bastiaannet E, Egan KM, de Craen AJ, 
Westendorp RG, Balducci L, et al. Management of primary 
metastatic breast cancer in elderly patients--an international 
comparison of oncogeriatric versus standard care. J Geriatr Oncol 
2014;5:252-259. 
45. National Cancer Institute. Focusing on older cancer patients: a 
clinical need and a research necessity. Available online: http://
www.cancer.gov/about-cancer/treatment/research/older-patients 
[Accessed 16/11/15].
46. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler 
J, Levine E, et al. Barriers to clinical trial participation by older 
women with breast cancer. J Clin Oncol 2003;21:2268-2275.
Cite this article as: Swaminathan D, Swaminathan V. Geriatric oncology: 
problems with under-treatment within this population. Cancer Biol Med 
2015;12:275-283. doi: 10.7497/j.issn.2095-3941.2015.0081
